Upcoming safety reports on wild-card drug Tysabri could dismiss previous safety concerns, generating significant upside for the company.
Both Avonex and Rituxan are groundbreaking drugs that lead their respective markets, giving Biogen Idec a solid foundation for stable growth.
Biogen Idec has the third-largest research and development budget amongst biotech firms, giving it the means to repeat its successes with Avonex and Rituxan.